Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
103 Results for "
kidney function
" in MedChemExpress (MCE) Product Catalog:
Products (103)
103 Results for "kidney function" in MCE Product Catalog:
Synonyms: PF-489791
Target:
Research Areas:
PF-00489791 (PF-489791) is a potent inhibitor of phosphodiesterase 5A with IC50 of 1.5 nM. PF-00489791 can enhance the relaxation of blood vessels within the kidney and so reduce blood pressure, improving renal function .
Cat. No.: HY-B2007
CAS No.: 79241-46-6
Research Areas:
Fluazifop-P-butyl is an orally active herbicide and ACCase inhibitor. Fluazifop-P-butyl blocks the formation of malonyl-CoA, disrupts lipid synthesis in sensitive plants, and exhibits concentration-dependent phytotoxicity to non-target maize seedlings. Fluazifop-P-butyl induces oxidative stress in male Wistar rats, impairs their liver and kidney functions, and disrupts testicular function .
Cat. No.: HY-W017018R
CAS No.: 3184-13-2
Category:
Cat. No.: HY-B0504S5
Synonyms: NSC13123-15N
Cat. No.: HY-P990250
Target:
Research Areas:
Cat. No.: HY-W661499
CAS No.: 37338-80-0
Category:
Cat. No.: HY-177388
CAS No.: 2797066-55-6
Target:
Research Areas:
Factor B-IN-6 is an orally active Factor B inhibitor. Factor B-IN-6 exhibits significant inhibitory activity against activation of the human serum serotonin pathway. Factor B-IN-6 can improve the severity of renal lesions and renal function, and reduce urinary protein in animal models. Factor B-IN-6 is useful for kidney disease research .
Synonyms: QR-01019
Target:
Research Areas:
Azilsartan mepixetil is the antagonist of angiotensin II receptor. Azilsartan mepixetil has stronger and longer blood pressure effect, more abvious and longer lasting heart rate lowering effect and high safety. Azilsartan mepixetil achieves ideal protective effect for heart and kidney functions. Azilsartan mepixetil has the potential for the research of hypertension, chronic heart failure and diabetic nephropathy (extracted from patent CN107400122A) .
Cat. No.: HY-W017018S3
CAS No.: 2483831-42-9
Cat. No.: HY-116887R
CAS No.: 443-72-1
Category:
Cat. No.: HY-A0003S
CAS No.: 1227162-34-6
Synonyms: CC-5013-d5
Lenalidomide-d5 (CC-5013-d5) is the d5-labeled Lenalidomide (HY-A0003). Lenalidomide (CC-5013) is an orally active immunomodulatory agent that binds CRBN as a molecular glue to alter substrate specificity, inducing ubiquitination and proteasome-dependent degradation of IKZF1, IKZF3 and CK1α. Lenalidomide induces apoptosis by degrading IKZF1/3, and activates p53 by degrading CK1α. Lenalidomide promotes IL-2 release and effector functions of CD8 + T/NK cells, while inhibiting TNF-α secretion and M1-type pyroptosis. Lenalidomide can be used in research related to hematological malignancies, acute liver failure and acute kidney injury .
Cat. No.: HY-151342
CAS No.: 3032193-12-4
Target:
Research Areas:
Ser@TPP@CUR is a Curcumin (HY-N0005) derivative. Ser@TPP@CUR effectively ameliorates injured renal tubular epithelial cells and improves renal functions of acute kidney injury (AKI) mice. Ser@TPP@CUR can be used for the research of AKI .
Cat. No.: HY-178951
CAS No.: 3069635-58-8
Research Areas:
STING-IN-17 (compound 10a) is an orally active STING (human STING IC50 = 29 nM, mouse STING IC50 = 15 nM) inhibitor. STING-IN-17 can inhibit the phosphorylation of STING, TBK1 and IRF3. STING-IN-17 dose dependently inhibits the mRNA expression of IP10, IFNB1 and ISG56. STING-IN-17 can reduce ROS and inhibit the expression of cleaved-PARP/caspase-3. STING-IN-17 can improve kidney function. STING-IN-17 can be used for research on inflammatory conditions such as acute kidney injury .
Cat. No.: HY-175985
CAS No.: 3030264-54-8
Target:
Research Areas:
MPO-IN-9 is a selective inhibitor of myeloperoxidase (MPO), with an IC50 value of 3.9 nM. MPO-IN-9 inhibits MPO-mediated ROS production and protects NO-dependent vascular function by blocking MPO's chlorination and peroxidation cycles. MPO-IN-9 can be used for the study of diseases such as chronic kidney disease (CKD), non-alcoholic steatohepatitis (NASH) .
Cat. No.: HY-168554
Target:
LYTACs STING IKK IFNAR CXCR Interleukin Related TNF Receptor
Research Areas:
STING Degrader-3 is a PROTAC-like STING degrader with a DC50 of 2.58 μM in THP-1 cells. STING Degrader-3 degrades STING protein via the lysosomal pathway. STING Degrader-3 functions as a non-degradative inhibitor in macrophages. STING Degrader-3 reduces the phosphorylation levels of TBK1 and IRF3, and downregulates the expression of IFN-β, CXCL10, IL-6, TNFα, IL-1β, ISG15 and ISG56. STING Degrader-3 exhibits renoprotective properties in a cisplatin-induced acute kidney injury model. STING Degrader-3 can be used in studies related to acute kidney injury. ((Pink: STING ligand (HY-168676); Blue: CRBN ligand (HY-126457); Black: linker (HY-W123015); CRBN ligand + linker: (HY-168677)) .
Cat. No.: HY-117372
CAS No.: 1445753-16-1
Target:
Research Areas:
DFL23448 is a selective transient receptor potential melastatin-8 (TRPM8) antagonist. DFL23448 shows IC50 values of 10 and 21 nM in hTRPM8 human embryonic kidney 293 cells activated by Cooling Agent 10 or cold. DFL23448 has limited activity (IC50 >10 μM) at transient receptor potential vanilloids TRPV1, TRPA1, or TRPV4 or at various G protein-coupled receptors. DFL23448 can modify bladder function and reduce bladder overactivity in awake rats .
Cat. No.: HY-178362
CAS No.: 3085155-69-4
Target:
Research Areas:
CAII/VII-IN-1 is an orally active hCA II (KI = 12.3 nM), and hCA VII (KI = 22.6 nM) inhibitor, showing no significant activity against hCA I. CAII/VII-IN-1 shows excellent neuroprotective activity in vivo Pilocarpine (HY-B0726A)-induced seizure model. CAII/VII-IN-1 can upregulate KCC2 and inhibit mTOR, exerting neuroprotective effects. CAII/VII-IN-1 does not show any significant neurotoxic effects or alterations in liver and kidney function. CAII/VII-IN-1 can be used for the study of epilepsy .
Cat. No.: HY-B0516A
CAS No.: 23964-58-1
Synonyms: Hoe-045 free base
Research Areas:
Articaine (Hoe-045) is a selective inhibitor of voltage-gated sodium channels (such as rNav1.4, hNav1.7, and rNav1.8), with an IC50 of 15.8 μM for open-state Na + channels, and IC50 of 40.6 μM and 378 μM for inactivated and resting-state Na + channels, respectively. Articaine exerts local anesthetic activity by inhibiting Na + influx to block nerve impulse conduction, and can also inhibit NF-κB activation and NLRP3 inflammasome pathways, exhibiting anti-inflammatory function. Articaine can be used in the study of dental local anesthesia and inflammatory-related diseases (such as acute kidney injury) .
Cat. No.: HY-A0003A
CAS No.: 1243329-97-6
Synonyms: CC-5013 hydrochloride
Lenalidomide hydrochloride (CC-5013 hydrochloride) is an orally active immunomodulatory agent that binds CRBN as a molecular glue to alter substrate specificity, inducing ubiquitination and proteasome-dependent degradation of IKZF1, IKZF3 and CK1α. Lenalidomide hydrochloride induces apoptosis by degrading IKZF1/3, and activates p53 by degrading CK1α. Lenalidomide hydrochloride promotes IL-2 release and effector functions of CD8 + T/NK cells, while inhibiting TNF-α secretion and M1-type pyroptosis. Lenalidomide hydrochloride can be used in research related to hematological malignancies, acute liver failure and acute kidney injury .
Cat. No.: HY-A0003S2
Synonyms: CC-5013-13C5,15N
Lenalidomide- 13C5, 15N (CC-5013- 13C5, 15N) is the 13C, 15N-labeled Lenalidomide (HY-A0003). Lenalidomide (CC-5013) is an orally active immunomodulatory agent that binds CRBN as a molecular glue to alter substrate specificity, inducing ubiquitination and proteasome-dependent degradation of IKZF1, IKZF3 and CK1α. Lenalidomide induces apoptosis by degrading IKZF1/3, and activates p53 by degrading CK1α. Lenalidomide promotes IL-2 release and effector functions of CD8 + T/NK cells, while inhibiting TNF-α secretion and M1-type pyroptosis. Lenalidomide can be used in research related to hematological malignancies, acute liver failure and acute kidney injury .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
